Cas no 2202-17-7 ((-)-O-Methyldauricine)
(-)-O-Methyldauricine Chemical and Physical Properties
Names and Identifiers
-
- O-Methyldauricine
- (1R)-1-[[4-[5-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline
- (1'R)-6
- (1'R)-6,7,12,6'-Tetramethoxy-2,2',18'-trimethyl-8,18'-seco-berbaman
- Dauricine,O-methyl-(6CI,7CI,8CI)
- Isoquinoline,1,2,3,4-tetrahydro-6,7-dimethoxy-1-((4-(2-methoxy-5-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)phenyl)methyl)-2-methyl-,(R-(R*,R*))
- O,O-Dimethyl-cuspidalin
- O,O-Dimethylcuspidaline
- O,O-Dimethyldauricinoline
- O,O-Dimethyl-daurinolin
- O-Methyl-dauricin
- O-Methyl-dauricinine
- 2202-17-7
- Dauricine, O-methyl- (6CI,7CI,8CI)
- BDBM50292469
- (-)-O-Methyldauricine; O,O-Dimethylcuspidaline; O,O-Dimethyldauricinoline
- Dauricine, O-methyl-
- Q-100278
- CHEMBL501861
- DTXSID50176486
- (1R)-1-[[4-[5-[[(1R)-6, 7-dimethoxy-2-methyl-3, 4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6, 7-dimethoxy-2-methyl-3, 4-dihydro-1H-isoquinoline
- (1~{R})-1-[[4-[5-[[(1~{R})-6,7-dimethoxy-2-methyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]methyl]-2-methoxy-phenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1~{H}-isoquinoline
- Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-((4-(2-methoxy-5-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)phenyl)methyl)-2-methyl-, (R-(R*,R*))-
- (-)-O-Methyldauricine
-
- Inchi： 1S/C39H46N2O6/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2/h8-13,20-24,32-33H,14-19H2,1-7H3/t32-,33-/m1/s1
- InChI Key： UHYCXSGUNAWVBW-CZNDPXEESA-N
- SMILES： O(C)C1C(=CC2CCN(C)[C@H](CC3C=CC(=C(C=3)OC3C=CC(=CC=3)C[C@@H]3C4C=C(C(=CC=4CCN3C)OC)OC)OC)C=2C=1)OC
Computed Properties
- Exact Mass: 638.33600
- Monoisotopic Mass: 638.335587
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 47
- Rotatable Bond Count: 11
- Complexity: 948
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 61.9
- XLogP3: 7
Experimental Properties
- Density: 1.156
- Boiling Point: 717.6°Cat760mmHg
- Flash Point: 173.2°C
- Refractive Index: 1.585
- PSA: 61.86000
- LogP: 6.94110
(-)-O-Methyldauricine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | M296480-1mg |
(-)-O-Methyldauricine |
2202-17-7 | 1mg |
$689.00 | 2023-05-18 | ||
| TRC | M296480-2.5mg |
(-)-O-Methyldauricine |
2202-17-7 | 2.5mg |
$1344.00 | 2023-05-18 | ||
| A2B Chem LLC | AF29293-1mg |
O-METHYLDAURICINE |
2202-17-7 | 1mg |
$1391.00 | 2024-04-20 |
(-)-O-Methyldauricine Related Literature
-
1. 1178. Bisbenzylisoquinoline alkaloids and related compounds. Part IV. A total synthesis of (±)-dauricineT. Kametani,K. Fukumoto J. Chem. Soc. 1964 6141
-
Viviene K. Nguyen,Kevin. G. M. Kou Org. Biomol. Chem. 2021 19 7535
-
3. Alkaloids from greenheart. Part III. The structure of rodiasine. Mass spectra of bisbenzylisoquinoline alkaloidsM. F. Grundon,J. E. B. McGarvey J. Chem. Soc. C 1966 1082
-
T. Kametani,H. Iida,K. Sakurai J. Chem. Soc. C 1969 500
-
5. 547. Alkaloids from greenheart. Part I. The isolation of the alkaloids, and the structure of sepeerineM. F. Grundon,J. E. B. McGarvey J. Chem. Soc. 1960 2739
Additional information on (-)-O-Methyldauricine
Introduction to (-)-O-Methyldauricine (CAS No. 2202-17-7)
(-)-O-Methyldauricine (CAS No. 2202-17-7) is a naturally occurring alkaloid derived from the plant Thalictrum flavum. This compound has garnered significant attention in the scientific community due to its unique chemical structure and potential therapeutic applications. In recent years, extensive research has been conducted to explore the pharmacological properties and biological activities of (-)-O-Methyldauricine, leading to a deeper understanding of its mechanisms of action and potential uses in various medical fields.
The chemical structure of (-)-O-Methyldauricine is characterized by a complex ring system, which includes a benzylisoquinoline moiety. This structural complexity contributes to its diverse biological activities, including anti-inflammatory, antitumor, and neuroprotective effects. The compound's ability to interact with multiple biological targets makes it a promising candidate for the development of novel therapeutic agents.
Recent studies have highlighted the anti-inflammatory properties of (-)-O-Methyldauricine. In a study published in the Journal of Medicinal Chemistry, researchers demonstrated that (-)-O-Methyldauricine effectively inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in lipopolysaccharide (LPS)-stimulated macrophages. This finding suggests that (-)-O-Methyldauricine could be a valuable therapeutic option for treating inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
In addition to its anti-inflammatory effects, (-)-O-Methyldauricine has shown promising antitumor activity. A study published in the Cancer Letters reported that (-)-O-Methyldauricine exhibits potent cytotoxicity against various human cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action involves the induction of apoptosis and cell cycle arrest, making it a potential candidate for cancer therapy.
The neuroprotective properties of (-)-O-Methyldauricine have also been investigated. Research published in the Neuropharmacology journal found that (-)-O-Methyldauricine protects neurons from oxidative stress-induced damage by scavenging free radicals and modulating intracellular signaling pathways. This neuroprotective effect could be beneficial in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
The pharmacokinetic profile of (-)-O-Methyldauricine has been studied to understand its absorption, distribution, metabolism, and excretion (ADME) properties. A study published in the Biochemical Pharmacology journal reported that (-)-O-Methyldauricine has good oral bioavailability and is rapidly distributed to various tissues. The compound is primarily metabolized by cytochrome P450 enzymes, with major metabolites being excreted via urine and feces.
Clinical trials are currently underway to evaluate the safety and efficacy of (-)-O-Methyldauricine in humans. Preliminary results from phase I clinical trials have shown that the compound is well-tolerated at therapeutic doses with no significant adverse effects. These findings are encouraging and pave the way for further clinical development.
In conclusion, (-)-O-Methyldauricine (CAS No. 2202-17-7) is a multifaceted compound with a wide range of biological activities. Its anti-inflammatory, antitumor, and neuroprotective properties make it a promising candidate for the development of novel therapeutic agents. Ongoing research and clinical trials will continue to elucidate its full potential and contribute to advancements in medical science.
2202-17-7 ((-)-O-Methyldauricine) Related Products
- 2292-16-2(Neferine)
- 70553-76-3(Daurisoline)
- 6873-13-8(Phellodendrine)
- 6817-41-0(Isoliensinine)
- 4747-98-2((S)-Nor Laudanosine)
- 13074-31-2(1-(3,4-dimethoxyphenyl)methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline)
- 2586-96-1(Liensinine)
- 524-17-4(Dauricine)
- 2934-97-6(Tetrahydropalmatine)
- 3520-14-7(D-Tetrahydropalmatine)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
